EA201792399A1 - Пептидные композиции и способы использования - Google Patents

Пептидные композиции и способы использования

Info

Publication number
EA201792399A1
EA201792399A1 EA201792399A EA201792399A EA201792399A1 EA 201792399 A1 EA201792399 A1 EA 201792399A1 EA 201792399 A EA201792399 A EA 201792399A EA 201792399 A EA201792399 A EA 201792399A EA 201792399 A1 EA201792399 A1 EA 201792399A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
peptide compositions
photoreceptor
fas
ways
Prior art date
Application number
EA201792399A
Other languages
English (en)
Other versions
EA035293B1 (ru
Inventor
Кагри Г. Бесирли
Александер Дж. Бриджес
Джон К. Фрешли
Вильям А. Ханке
Линда Л. Джонсон
Френсис Х. Смит
Итан Сильвен
Дэвид Н. Закс
Original Assignee
ОЭнЭл ТЕРАПЬЮТИКС, ИНК.
Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ОЭнЭл ТЕРАПЬЮТИКС, ИНК., Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган filed Critical ОЭнЭл ТЕРАПЬЮТИКС, ИНК.
Publication of EA201792399A1 publication Critical patent/EA201792399A1/ru
Publication of EA035293B1 publication Critical patent/EA035293B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Pest Control & Pesticides (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Plant Pathology (AREA)
  • Agronomy & Crop Science (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

В данном документе предоставлены композиции, включающие пептиды, их фармацевтические препараты и способы предотвращения с их помощью смерти фоторецепторов и защиты клеток сетчатки, включая, но без ограничения, фоторецепторные и пигментный эпителий сетчатки, от Fas- или TRAIL-опосредованного апоптоза.
EA201792399A 2015-05-01 2016-04-29 Пептидные композиции и способы использования EA035293B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562155711P 2015-05-01 2015-05-01
PCT/US2016/030098 WO2016178993A1 (en) 2015-05-01 2016-04-29 Peptide compositions and methods of use

Publications (2)

Publication Number Publication Date
EA201792399A1 true EA201792399A1 (ru) 2018-05-31
EA035293B1 EA035293B1 (ru) 2020-05-26

Family

ID=57217771

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201792399A EA035293B1 (ru) 2015-05-01 2016-04-29 Пептидные композиции и способы использования
EA202090184A EA202090184A3 (ru) 2015-05-01 2016-04-29 Пептидные композиции и способы использования

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA202090184A EA202090184A3 (ru) 2015-05-01 2016-04-29 Пептидные композиции и способы использования

Country Status (22)

Country Link
US (4) US10508134B2 (ru)
EP (2) EP3288379B1 (ru)
JP (2) JP6884755B2 (ru)
KR (2) KR20240046280A (ru)
CN (2) CN107708416B (ru)
AU (1) AU2016258837B2 (ru)
BR (1) BR112017023479A2 (ru)
CA (1) CA2984154A1 (ru)
CY (1) CY1124911T1 (ru)
DK (1) DK3288379T3 (ru)
EA (2) EA035293B1 (ru)
ES (1) ES2906173T3 (ru)
HK (1) HK1251979A1 (ru)
HR (1) HRP20220138T1 (ru)
HU (1) HUE057883T2 (ru)
LT (1) LT3288379T (ru)
MX (1) MX2017014075A (ru)
PL (1) PL3288379T3 (ru)
PT (1) PT3288379T (ru)
RS (1) RS62866B1 (ru)
SI (1) SI3288379T1 (ru)
WO (1) WO2016178993A1 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10508134B2 (en) 2015-05-01 2019-12-17 Onl Therapeutics, Inc. Peptide compositions and methods of use

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3768301A4 (en) * 2018-03-20 2022-06-08 ONL Therapeutics, Inc. COMPOSITIONS AND METHODS FOR FAS INHIBITION
EP3810082A1 (en) * 2018-06-19 2021-04-28 Cella Therapeutics, LLC Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension
CA3162324A1 (en) * 2019-12-18 2021-06-24 Rhett M. Schiffman Drug delivery systems comprising a neurotrophic agent, an apoptosis signaling fragment inhibitor (fas) or fas ligand (fasl) inhibitor, a tumor necrosis factor-.alpha. (tnf-.alpha.) or tnf receptor inhibitor, a mitochondrial peptide, an oligonucleotide, a chemokine inhibitor, or a cysteine-aspartic protease inhibitor
WO2023129766A1 (en) * 2021-12-27 2023-07-06 Onl Therapeutics, Inc. Sfasl for inhibiting rpe cell death and associated disorders
WO2024031024A1 (en) * 2022-08-05 2024-02-08 Onl Therapeutics, Inc. Peptide compositions and methods of use
WO2024031022A2 (en) * 2022-08-05 2024-02-08 Onl Therapeutics, Inc. Peptide compositions and methods of use

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5532123A (en) * 1990-07-11 1996-07-02 New York University Receptor-type phosphotyrosine phosphatase-γ
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
JP3187201B2 (ja) * 1992-05-14 2001-07-11 三共株式会社 Ｃ末端にプロリンアミドを有するペプチドの製法
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5631237A (en) 1992-12-22 1997-05-20 Dzau; Victor J. Method for producing in vivo delivery of therapeutic agents via liposomes
JP3460863B2 (ja) 1993-09-17 2003-10-27 三菱電機株式会社 半導体装置の製造方法
US5714353A (en) 1994-05-24 1998-02-03 Research Corporation Technologies, Inc. Safe vectors for gene therapy
US5527928A (en) 1994-09-30 1996-06-18 Nantz; Michael H. Cationic transport reagents
US5650096A (en) 1994-12-09 1997-07-22 Genzyme Corporation Cationic amphiphiles for intracellular delivery of therapeutic molecules
US5719131A (en) 1994-12-09 1998-02-17 Genzyme Corporation Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules
US5711964A (en) 1995-06-07 1998-01-27 United States Of America Method for the intracellular delivery of biomolecules using liposomes containing cationic lipids and vitamin D
US5705385A (en) 1995-06-07 1998-01-06 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US6001962A (en) 1996-11-15 1999-12-14 The Regents Of The University Of California Modified Fas ligands
US7091047B2 (en) * 1997-05-23 2006-08-15 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity
US6363020B1 (en) 1999-12-06 2002-03-26 Virage Logic Corp. Architecture with multi-instance redundancy implementation
US6480428B2 (en) 2000-12-19 2002-11-12 Winbond Electronics Corporation Redundant circuit for memory device
EP1730186A2 (en) 2004-03-31 2006-12-13 Xencor, Inc. Bmp-7 variants with improved properties
CA2563691A1 (en) 2004-04-23 2005-12-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Cell death modulation via antagonists of fasl and fas activation
JP4968954B2 (ja) 2005-05-10 2012-07-04 アルコン，インコーポレイテッド 活性成分、ポロキサマー界面活性剤もしくはメロキサポール界面活性剤およびグリコールを含有する懸濁処方物、ならびに眼の障害を処置するための医薬の製造のためのその使用
CN101355876B (zh) * 2005-11-09 2012-09-05 康宾纳特克斯公司 一种适用于眼部给药的组合物
US20080280834A1 (en) 2005-12-01 2008-11-13 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compounds and methods for inhibiting apoptosis
US20110039773A1 (en) * 2007-12-21 2011-02-17 Stryker Biotech BMP Mutants with Decreased Susceptibility to Noggin
CA2754065C (en) 2009-03-03 2017-07-11 The Regents Of The University Of Michigan Methods of inhibiting photoreceptor apoptosis
US20120101046A1 (en) * 2009-03-30 2012-04-26 Santen Pharmaceutical Co., Ltd. Prophylactic or therapeutic agent for retinal disease and method for prophylaxis or therapy of retinal disease using jnk (c-jun amino-terminal kinase) - inhibitory peptide, and use of the peptide
EP2462128B1 (en) * 2009-08-04 2016-09-21 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
JP6091435B2 (ja) 2011-02-22 2017-03-08 カリフォルニア インスティチュート オブ テクノロジー アデノ随伴ウイルス（ａａｖ）ベクターを用いたタンパク質の送達
KR20140038501A (ko) * 2011-06-06 2014-03-28 키네타 원, 엘엘씨 Shk-기초된 제약학적 조성물 및 이들을 제조하고 이용하는 방법
CA2861543C (en) 2012-01-18 2022-05-31 Governing Council Of The University Of Toronto Novel peptides and methods and uses thereof for preventing retinal disorders
BR112014031923B1 (pt) * 2012-06-21 2022-02-08 Daewoong Pharmaceutical Co., Ltd. Uso de uma composição compreendendo pelo menos um tnfri modificado ou fragmento tnfri modificado, uso de uma formulação tópica e uso de uma composição
US20150265679A1 (en) * 2012-11-02 2015-09-24 The United States Of America, As Represented By Secretary, Department Of Health And Human Services Method of reducing adverse effects in a cancer patient undregoing treatment with a mek inhibitor
US20180024145A1 (en) 2015-02-05 2018-01-25 Immunarray USA, Inc. Methods and compositions for diagnosing brain injury or neurodegeneration
EP3288379B1 (en) 2015-05-01 2021-11-03 Onl Therapeutics, Inc. Peptide compositions and methods of use
US20190201500A1 (en) 2015-05-01 2019-07-04 Onl Therapeutics, Inc. Compositions and methods of fas inhibition
MX2019000221A (es) 2016-07-05 2020-02-07 Univ Massachusetts Suministro genetico de sfasl mediado por aav2 como una terapia neuro-protectora en el glaucoma.
EP3768301A4 (en) 2018-03-20 2022-06-08 ONL Therapeutics, Inc. COMPOSITIONS AND METHODS FOR FAS INHIBITION
EP3810082A1 (en) 2018-06-19 2021-04-28 Cella Therapeutics, LLC Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10508134B2 (en) 2015-05-01 2019-12-17 Onl Therapeutics, Inc. Peptide compositions and methods of use
US10829518B2 (en) 2015-05-01 2020-11-10 Onl Therapeutics. Inc. Peptide compositions and methods of use

Also Published As

Publication number Publication date
CA2984154A1 (en) 2016-11-10
JP2021120400A (ja) 2021-08-19
EP3997981A1 (en) 2022-05-18
US20200123201A1 (en) 2020-04-23
JP6884755B2 (ja) 2021-06-09
KR20170140383A (ko) 2017-12-20
EA202090184A2 (ru) 2020-05-31
LT3288379T (lt) 2022-02-25
JP2018514590A (ja) 2018-06-07
CN107708416A (zh) 2018-02-16
MX2017014075A (es) 2018-07-06
US10508134B2 (en) 2019-12-17
EP3288379A4 (en) 2018-10-24
CN113651873A (zh) 2021-11-16
US20230287052A1 (en) 2023-09-14
DK3288379T3 (da) 2022-02-07
ES2906173T3 (es) 2022-04-13
BR112017023479A2 (pt) 2018-07-24
EA202090184A3 (ru) 2020-07-31
PL3288379T3 (pl) 2022-03-07
US20180291062A1 (en) 2018-10-11
US20210094985A1 (en) 2021-04-01
CY1124911T1 (el) 2023-01-05
US11597749B2 (en) 2023-03-07
KR102652804B1 (ko) 2024-04-01
EP3288379B1 (en) 2021-11-03
HRP20220138T1 (hr) 2022-05-27
SI3288379T1 (sl) 2022-06-30
HK1251979A1 (zh) 2019-05-10
HUE057883T2 (hu) 2022-06-28
AU2016258837A1 (en) 2017-11-09
EA035293B1 (ru) 2020-05-26
US10829518B2 (en) 2020-11-10
EP3288379A1 (en) 2018-03-07
PT3288379T (pt) 2022-02-08
WO2016178993A1 (en) 2016-11-10
CN107708416B (zh) 2021-06-29
AU2016258837B2 (en) 2020-12-03
RS62866B1 (sr) 2022-02-28
KR20240046280A (ko) 2024-04-08

Similar Documents

Publication Publication Date Title
EA201792399A1 (ru) Пептидные композиции и способы использования
EA202091898A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
EA201891083A1 (ru) Составы антител к cd38 для подкожного введения и их применение
EA201792500A1 (ru) Aav-опосредованная экспрессия антител против гриппа и способы их использования
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
EA201790533A1 (ru) Способы и композиции для ослабления иммунных ответов против вирусного вектора для переноса, предназначенного для модулирования экспрессии генов
EA201692512A1 (ru) Способы и композиции для лечения синтетическими наноносителями и ингибиторами иммунной контрольной точки
EA201690152A1 (ru) Ингибиторы ido
MX2019015018A (es) Composiciones que comprenden curones y usos de los mismos.
BR112016025819A2 (pt) vetores de vírus adeno-associados para o tratamento de doenças de depósito lisossômico
EA201790922A1 (ru) Ингибиторы бромодомена
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
CL2016002839A1 (es) Derivados de carboxamida
EA201790565A1 (ru) Композиции и способы для лечения предраковых поражений кожи
EA201991377A1 (ru) Композиции универсальной вакцины против гриппа
ZA201703467B (en) Methods of treating ocular conditions
EA202091567A1 (ru) Химерные белки мти
EA201600093A1 (ru) Дигидроксифенильные нейромедиаторные соединения, композиции и способы
EP3302531A4 (en) RECOMBINANT IMMUNE TOLERANCE ELASTINE-LIKE PEPTIDES WITHOUT IMMUNE TOLERANCE AND METHODS OF USE
EA201790771A1 (ru) Фармацевтические композиции длительного действия для лечения гепатита c
WO2019036725A3 (en) PEPTIDE INHIBITORS OF TAU AGGREGATION
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
EA202090971A1 (ru) Способы применения и композиции, содержащие дулаглутид